Drug Profile
SF1
Alternative Names: Sonoflora 1; Sonosensitizing agent - SonneMedLatest Information Update: 15 Sep 2015
Price :
$50
*
At a glance
- Originator SonneMed
- Class
- Mechanism of Action Singlet oxygen stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer
Most Recent Events
- 15 Sep 2015 Discontinued - Phase-I/II for Breast cancer (Late-stage disease) in USA (Sublingual)
- 08 Sep 2008 Phase-I/II clinical trials in Advanced breast cancer in USA (Sublingual)